CRMLW vs CRIS vs MP vs TGTX vs RCUS

For growth investors, TG Therapeutics, Inc.

(TGTX) is the stronger pick with 87. 3% revenue growth year-over-year, versus -13. 4% for Curis, Inc. (CRIS). TG Therapeutics, Inc. (TGTX) offers the better valuation at 15. 5x trailing P/E (32. 9x forward), making it the more compelling value choice. Analysts rate MP Materials Corp. (MP) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, TG Therapeutics, Inc.

is actually cheaper at 32. 9x.

Over the past 5 years, Critical Metals Corp.

(CRMLW) delivered a total return of +42. 3%, compared to -99. 7% for Curis, Inc. (CRIS). Over 10 years, the gap is even starker: CRMLW returned +41. 9% versus CRIS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TG Therapeutics, Inc.

(TGTX) is the lower-risk stock at 0. 84β versus Critical Metals Corp. 's 2. 89β — meaning CRMLW is approximately 245% more volatile than TGTX relative to the S&P 500. On balance sheet safety, Arcus Biosciences, Inc. (RCUS) carries a lower debt/equity ratio of 16% versus 44% for MP Materials Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TG Therapeutics, Inc.

(TGTX) is pulling ahead at 87. 3% versus -13. 4% for Curis, Inc. (CRIS). On earnings-per-share growth, the picture is similar: TG Therapeutics, Inc. grew EPS 1747% year-over-year, compared to -154. 6% for Critical Metals Corp.. Over a 3-year CAGR, TGTX leads at 504. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TG Therapeutics, Inc.

(TGTX) is the more profitable company, earning 72. 6% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 72. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TGTX leads at 20. 0% versus -348. 4% for CRIS. At the gross margin level — before operating expenses — CRIS leads at 99. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, TG Therapeutics, Inc.

(TGTX) trades at 32. 9x forward P/E versus 254. 2x for MP Materials Corp. — 221. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TGTX: 26. 7% to $54. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, TG Therapeutics, Inc.

(TGTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 84), +434. 4% 10Y return). Curis, Inc. (CRIS) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TGTX: +434. 4%, CRIS: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CRMLW (Basic Materials) and CRIS (Healthcare) and MP (Basic Materials) and TGTX (Healthcare) and RCUS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CRMLW is a small-cap quality compounder stock; CRIS is a small-cap quality compounder stock; MP is a mid-cap high-growth stock; TGTX is a small-cap high-growth stock; RCUS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.